EUVIMEDEUVIMED entdecken
Crossref

Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes

Kevin Y Heo, Rahul K Goel, Alyssa Woltemath, Andrew Fuqua, Bryce T Hrudka, Omar Syed, Emilio Arellano, Ajay Premkumar, Jacob M Wilson

The Journal of Arthroplasty · 2025

DOI: 10.1016/j.arth.2024.10.099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2025. Verfasst von Kevin Y Heo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists have emerged as a powerful diabetic treatment adjunct; however, their effects on outcomes following total hip arthroplasty (THA) are not well known. This study aimed to compare the risk of complications in patients who had type 2 diabetes mellitus (DM) who were on GLP-1 agonists with those who were not on these medications. METHODS: In total, 14,065 patients who had type 2 DM undergoing primary THA between 2016 and 2021 were retrospectively reviewed using a national database. Propensity score matching was employed at a 1:4 ratio to match patients who used GLP-1 agonists (n = 812) to those who did not (n = 3,248). Patients were matched on age, sex, insulin status, presence of other diabetic medications, comorbidities, and smoking status. Multivariable logistic regressions were performed to examine 90-day and 1-year THA outcomes between groups. RESULTS: Patients who were not on GLP-1 agonists exhibited increased rates of extended hospital stays (≥3 days) (odds ratio 1.25, P = 0.01). Patients who were on GLP-1 agonists exhibited no significant differences in surgical or medical complication rates at 90 days compared to those not on GLP-1 agonists. There were also no significant differences in rates of all-cause revision THA, aseptic revision THA, or periprosthetic joint infection during the 1-year postoperative period. CONCLUSIONS: This study demonstrated that GLP-1 agonists were not associated with increased risks for medical or surgical complications in patients who had DM undergoing THA and were associated with lower rates of extended hospital stays after surgery. This study provides additional evidence regarding the association of GLP-1 agonist use before THA with postoperative outcomes. Given the potential for increased glycemic control and weight loss, more data are needed to delineate the role of GLP-1 agonists in the optimization of patients who have DM before THA to minimize postoperative complications. LEVEL OF EVIDENCE: Level III, retrospective cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, HipDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsPostoperative ComplicationsHypoglycemic AgentsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPropensity Score

Stichwörter der Autor:innen

GLP-1 receptor agonistglucagon-like peptide-1 receptor agonistsurgical complicationstotal hip arthroplastytype 2 diabetes mellitus

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, Georgia.
  • Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, North Carolina.
  • Department of Orthopaedic Surgery, New York Medical College, Valhalla, New York.

Zitieren

APA

Heo, K. Y., Goel, R. K., Woltemath, A., Fuqua, A., Hrudka, B. T., Syed, O., Arellano, E., Premkumar, A., & Wilson, J. M. (2025). Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2024.10.099

Vancouver

Heo KY, Goel RK, Woltemath A, Fuqua A, Hrudka BT, Syed O, et al. Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes. The Journal of Arthroplasty. 2025. doi:10.1016/j.arth.2024.10.099

BibTeX
@article{Heo2025,
  author = {Heo, Kevin Y and Goel, Rahul K and Woltemath, Alyssa and Fuqua, Andrew and Hrudka, Bryce T and Syed, Omar and Arellano, Emilio and Premkumar, Ajay and Wilson, Jacob M},
  title = {Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes},
  journal = {The Journal of Arthroplasty},
  year = {2025},
  doi = {10.1016/j.arth.2024.10.099}
}
Kostenlos starten →